RxDoctor Payments Data

Chi Tai Lau, MD

Family Medicine · Zwolle, LANPI 1750340592

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 101 payments — averaging $12.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$936
  • Novartis$61
  • Lilly USA, LLC$42
  • Abbott$36
  • Otsuka America Pharmaceutical, Inc.$33
  • Mylan Specialty L.p.$22
  • plus $179 from 10 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,309 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,106
Medicare patients
74
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$171,121
OzempicSemaglutide94$96,621
JanuviaSitagliptin Phosphate171$94,786
EntrestoSacubitril/Valsartan115$67,784
TrulicityDulaglutide66$61,063
JardianceEmpagliflozin80$45,067
LinzessLinaclotide72$44,692
Repatha SureclickEvolocumab50$30,180
XareltoRivaroxaban63$27,789
FarxigaDapagliflozin Propanediol44$27,031
TradjentaLinagliptin74$26,241
MyrbetriqMirabegron71$23,338
MounjaroTirzepatide15$18,718
LybalviOlanzapine/Samidorphan Malate11$18,640
Combivent RespimatIpratropium/Albuterol Sulfate25$16,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$171,121368 claims
Novo NordiskOzempic$16$96,62194 claims
Lilly USA, LLCTrulicity, Mounjaro$42$79,78181 claims
NovartisEntresto$61$67,784115 claims
AbbVieLinzess, Vraylar$22$59,18090 claims
Alkermes, Inc.Lybalvi$18$18,64011 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33$11,04816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Zwolle

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →